Shots:
Natera has entered into collaboration with Angiex to use longitudinal Signatera testingfor circulating tumor DNA (ctDNA) to assess treatment response monitoring during AGX101 treatment
AGX101 is designed to target TM4SF1-expressing tumor cells & tumor-associated endothelial cells, delivering a cytotoxic payload to both the tumor & its vasculature
Angiex is conducting a P-I trial of…
Shots:
Chai Discovery has entered a collaboration with BMS to advance the discovery of therapeutic antibodies using artificial intelligence
As per the deal, BMS will leveraging Chai’s AI models and platform capabilities including its molecular folding & design models to support the discovery of antibody candidates across its portfolio and to support the development of…
Shots:
OmniAb has entered a global collaboration & license agreement with Eli Lilly for a new ion channel program, leveraging OmniAb’s discovery & screening platform to identify next-generation therapeutics targeting ion channels
The therapeutic target and modality remain undisclosed, while OmniAb will contribute its established expertise and technology in ion channel discovery & screening
As…
Shots:
Almirall & CrystalO have partnered to advance drug discovery research in medical dermatology, leveraging CrystalO's scientific expertise in ion channels with Almirall's experience in medical dermatology R&D
As per the deal, CrystalO will use its AI & structure-based drug discovery platform for compound discovery, optimization, IND-enabling studies, & early clinical development through PoC. Almirall…
Shots:
Ono has entered into a drug discovery partnership & option agreement with Mediar Therapeutics to develop novel antibody therapeutics for fibro-inflammatory diseases
As per the deal, Mediar will conduct research using its fibrosis-focused research platform, while Ono will gain exclusive worldwide option rights to select candidates for development, manufacturing, & commercialization
The partnership will…
Shots:
Schrödinger has entered into a strategic agreement with BMS to deploy Bunsen, its agentic AI co-scientist, across BMS's research organization, expanding the companies' long-standing partnership
As per the deal, Schrödinger will work with BMS to develop new Bunsen capabilities alongside its computational technologies for large-scale chemical exploration & RetroSynth, its AI-driven synthesis planning platform …
Shots:
SOPHiA GENETICS has entered a global collaboration with AstraZeneca to develop, validate, & commercialize two companion diagnostics (CDx) supporting precision oncology therapies
The multi-year collaboration will leverage SOPHiA’s decentralized clinical trial assays & CDx capabilities to advance development & commercialization of the CDx programs
As per the deal, SOPHiA GENETICS will develop its Solid Tumor…
The pharmaceutical industry is entering a new era where innovation is no longer driven by individual organisations alone. From drug discovery and clinical research to manufacturing, regulatory compliance, digital transformation, and global commercialisation, success increasingly depends on strategic partnerships that combine expertise, technology, and shared ambition.
The Global Pharma Partnering Summit 2026 serves as a…
Shots:
Relation has entered a strategic research collaboration with GSK to generate large-scale human cellular perturbation datasets to understand disease biology & discover novel therapeutic targets
Relation will generate large-scale perturbation datasets using advanced human cellular disease models & experimental systems to develop, validate, & train foundation models, incl. MORGAN, to investigate disease biology &…
Shots:
J&J has entered strategic agreements & collaboration with Sail to advance its lead immune-mediated disease program & in vivo CAR-T platform, with the potential to expand the platform across additional therapeutic targets
As per the deal, Sail will receive initial payments of $785M, incl. a $465M equity investment, with additional contingent payments of ~$140M…

